Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP

Profound Medical Corp.

2024-FY EPS reported $1.12 revenue$10,680,000

Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.
Preliminary FY2024 revenue $11.1-11.2M vs $7.2M in FY2023.
As of Jan 1, 2025, transitioning from IFRS to US GAAP; will file US domestic forms (10-K, 10-Q, 8-K).
TULSA procedure now reimbursed at Urology APC Level 7 across multiple treatment settings.
Company to present at JPM 2025 on Jan 16 at 11:15 a.m. PT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.